About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Signup For Free
Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for Obesity
Ascletis Pharma announced the first participants have been dosed in a Phase IIa clinical trial (NCT07002905) evaluating ASC30, a novel small molecule ...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for Obesity